Ocuphire Pharma Results Presentation Deck
RM
19
Summary of Positive MIRA-2 Phase 3 Results for Nyxol Eye Drops
Sustained Efficacy with a Favorable Safety Profile in Reversing Mydriasis with Nyxol
●
●
●
●
Met primary endpoint at 90 minutes with high statistical significance with 2 drops
of Nyxol
Met all key secondary endpoints with high statistical significance
1.
Efficacy for all 3 mydriatic agents - phenylephrine, tropicamide, and ParemydⓇ
2.
Efficacy in both light and dark iris colors.
3.
Efficacy with only one Nyxol drop in non-study eye
Favorable safety profile
Mild, transient conjunctival hyperemia reported in the first hour and declined steadily thereafter
No serious AEs, no drop-outs from AEs, no systemic AEs were observed in ≥ 5% of subjects
Validates Nyxol mechanism of action, therapeutic effect, and safety profile in the
other two indications of presbyopia and night vision disturbances
-
MIRA-2 Topline Reports (TLR)
Ocuphire
PHARMAView entire presentation